Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical's First-Quarter Net Profit More Than Doubled

07/30/2021 | 02:57am EDT

By Kosaku Narioka

Takeda Pharmaceutical Co. said Friday that its first-quarter net profit more than doubled compared with the same period a year earlier thanks partly to sales of diabetes-related products.

The Japanese drug maker said that net profit for the quarter ended June 30 rose to 200.38 billion yen ($1.83 billion) from Y82.51 billion a year earlier. That beat the estimate of Y138.42 billion from a poll of analysts by S&P Global Market Intelligence.

First-quarter revenue increased 18% from a year earlier to Y949.60 billion.

Takeda sold diabetes products in Japan to Teijin Pharma Ltd. for Y133.0 billion in April, helping its quarterly earnings.

Takeda's operating profit margin improved to 26.2% from 20.9% a year earlier.

Takeda maintained its revenue and net-profit forecasts for its fiscal year ending March. It expects revenue to increase 5.4% to Y3.370 trillion and net profit to fall 34% to Y250.00 billion.

Write to Kosaku Narioka at kosaku.narioka@wsj.com

(END) Dow Jones Newswires

07-30-21 0256ET

All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09/16TAKEDA PHARMACEUTICAL : Continues to Advance Growth Strategy with Sale Of Non-Co..
PU
09/16TAKEDA PHARMACEUTICAL : EXKIVITY (mobocertinib) Approved by U.S. FDA as the Firs..
AQ
09/16THERMO FISHER SCIENTIFIC : FDA Approves Tissue-Based NGS Companion Diagnostic fo..
AQ
09/15TAKEDA PHARMACEUTICAL : U.S. FDA approves Takeda's lung cancer therapy
RE
09/15TAKEDA PHARMACEUTICAL : U.S. FDA approves Takeda's lung cancer therapy
RE
09/15TAKEDA PHARMACEUTICAL : Exkivity Wins FDA Approval for Treatment of Lung Cancer ..
MT
09/15TAKEDA PHARMACEUTICAL : EXKIVITY™ (mobocertinib) Approved by U.S. FDA as t..
BU
09/15Food and Drug Administration Approves Takeda’s EXKIVITY™ (Mobocertinib) for t..
CI
09/13Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO
RE
09/13TAKEDA PHARMACEUTICAL : Novavax Statement on Takeda Agreement to Provide 150 Mil..
AQ
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 387 B 30 784 M 30 784 M
Net income 2022 253 B 2 303 M 2 303 M
Net Debt 2022 3 472 B 31 564 M 31 564 M
P/E ratio 2022 23,8x
Yield 2022 4,72%
Capitalization 5 996 B 54 566 M 54 504 M
EV / Sales 2022 2,80x
EV / Sales 2023 2,66x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 813,00 JPY
Average target price 4 844,67 JPY
Spread / Average Target 27,1%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED1.54%54 566
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604